SPOTLIGHT: Prometheus is IPO bound


Prometheus Laboratories, which is making a name for itself in the arena of diagnostic tests and personalized medicine, has filed for an IPO designed to raise up to $100 million. Prometheus specializes in treating gastrointestinal disorders, integrating drugs and diagnostics. The company's revenue rose to $165 million in the first nine months of this year, with earnings down for the same period. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.